ASH 2022 | Inadequate toxicity reporting in acute leukemia clinical trials

Nicole Kuderer • 12 Dec 2022

ASH 2022

Leukemia

Nicole Kuderer, MD, MSc, Advanced Cancer Research Group, Seattle, WA, discusses inconsistencies in toxicity reporting across clinical trials, and highlights results from a systematic review of Phase III clinical trials, which called attention to abstracts using minimizing language when describing high rates of serious adverse events (AEs). Dr Kuderer calls for objectivity and transparency in toxicity reporting, particularly as this language can disproportionately influence the treatment decision-making process for clinicians. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Spectrum: Consultancy; Pfizer: Consultancy; Janssen: Consultancy; Seattle Genetics: Consultancy; Sandoz: Consultancy; G1 Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy; Beyond Spring: Consultancy; Amgen: Research Funding.